Sanofi (NASDAQ:SNY) Coverage Initiated at BNP Paribas

Equities research analysts at BNP Paribas initiated coverage on shares of Sanofi (NASDAQ:SNY) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $65.00 price target on the stock. BNP Paribas’ price objective points to a potential upside of 27.28% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.33.

Sanofi Stock Down 1.5 %

Shares of SNY traded down $0.77 during trading hours on Tuesday, reaching $51.07. 2,447,493 shares of the stock traded hands, compared to its average volume of 2,329,360. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The company has a market cap of $129.02 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 1.01 and a beta of 0.57. The stock has a fifty day simple moving average of $54.94 and a 200 day simple moving average of $52.31. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities analysts forecast that Sanofi will post 4.36 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Sanibel Captiva Trust Company Inc. bought a new position in shares of Sanofi in the first quarter worth $208,000. SG Americas Securities LLC lifted its holdings in Sanofi by 57.8% during the 1st quarter. SG Americas Securities LLC now owns 28,411 shares of the company’s stock worth $1,576,000 after purchasing an additional 10,403 shares in the last quarter. Parsons Capital Management Inc. RI grew its stake in Sanofi by 11.8% during the first quarter. Parsons Capital Management Inc. RI now owns 14,715 shares of the company’s stock valued at $816,000 after acquiring an additional 1,550 shares in the last quarter. Simplicity Wealth LLC purchased a new stake in Sanofi in the 1st quarter worth approximately $221,000. Finally, GAMMA Investing LLC increased its holdings in shares of Sanofi by 58.7% in the first quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock worth $336,000 after purchasing an additional 2,241 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.